Please provide your email address to receive an email when new articles are posted on . “Clinical practice guidelines recommend adding second-line agents, such as DPP-IV inhibitors, if glycemic ...
Merck and Pfizer announced at the American Diabetes Association 77th Scientific Sessions, San Diego, CA, that two Phase 3 studies evaluating ertugliflozin in adults with type 2 diabetes met their ...
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- New data were presented at the American Diabetes Association (ADA) 70 th Annual Scientific Sessions from a study comparing ...
Adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes who are not adequately controlled on metformin or sitagliptin alone or in patients already being treated with ...
Janumet™ (MK-0431A) combines two OADs with complementary mechanisms of action to improve glycemic control, sitagliptin and metformin. The tablet was designed in order to be bioequivalent to ...
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved JANUMET ® XR ...
Results presented at the 77th Scientific Sessions of the American Diabetes Association are for combinations with ertugliflozin, an investigational SGLT2 inhibitor before FDA. Ertugliflozin, the ...
Do not use if you have ever had an allergic reaction to SITAGLIPTIN/METFORMIN MYLAN or any of the ingredients listed at the end of the CMI. Talk to your doctor if you have any other medical conditions ...
Researchers from the US have shown that combination therapy with sitagliptin and metformin results in a substantial and additive glycemic improvement in patients with type 2 diabetes. Sitagliptin, a ...
New data presented at the American Diabetes Association 70 th Annual Scientific Sessions WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- New data were presented at the American Diabetes Association (ADA) ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. SITAGLIPTIN/METFORMIN XR MYLAN contains the active ingredients ...
As a new class of OADs, DPP-4 inhibitors have many important advantages over other currently available antidiabetic drugs. Compared with currently available insulin secretagogues, DPP-4 inhibitors, by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results